{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:22Z","timestamp":1786985242466,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.biopha.2022.112650","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T11:34:06Z","timestamp":1642592046000},"page":"112650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine"],"prefix":"10.1016","volume":"147","author":[{"given":"Thuy Trang","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang Ho Thu","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Mai","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh Ngoc","family":"Phuoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuong Kha","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giau Van","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112650_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-59261-5_1","article-title":"SARS-CoV-2 (COVID-19): beginning to understand a new virus","volume":"1321","author":"Van","year":"2021","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.biopha.2022.112650_bib2","unstructured":"WHO, Coronavirus disease (COVID-19) Dashboard. [cited 2021 November 04], 2021."},{"key":"10.1016\/j.biopha.2022.112650_bib3","first-page":"1","article-title":"Microneedles enable the development of skin-targeted vaccines against coronaviruses and influenza viruses","author":"Nguyen","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2022.112650_bib4","first-page":"1","article-title":"Additional diagnostic testing of the 2019 novel coronavirus (SARS-CoV-2)","author":"Vo","year":"2020","journal-title":"Mol. Cell Toxicol."},{"key":"10.1016\/j.biopha.2022.112650_bib5","doi-asserted-by":"crossref","first-page":"n1871","DOI":"10.1136\/bmj.n1871","article-title":"Covid-19: 1.5 million children have been orphaned by pandemic, study estimates","volume":"374","author":"Taylor","year":"2021","journal-title":"Br. Med. J."},{"issue":"25","key":"10.1016\/j.biopha.2022.112650_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib7","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Sci. Rep."},{"issue":"10263","key":"10.1016\/j.biopha.2022.112650_bib8","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson","year":"2020","journal-title":"Lancet"},{"issue":"10317","key":"10.1016\/j.biopha.2022.112650_bib9","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112650_bib10","unstructured":"Singanayagam, A., et al., Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. The Lancet Infectious Diseases."},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10020-021-00317-z","article-title":"Heterologous vaccine interventions: boosting immunity against future pandemics","volume":"27","author":"Mar\u00edn-Hern\u00e1ndez","year":"2021","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.112650_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.sapharm.2020.10.009","article-title":"COVID-19 and compromised tuberculosis control efforts: Highlighting the need for integration of community pharmacies into the national tuberculosis programme","volume":"17","author":"Hoai","year":"2021","journal-title":"Res. Soc. Adm. Pharm."},{"key":"10.1016\/j.biopha.2022.112650_bib13","article-title":"Mix and match COVID-19 vaccines: potential benefit and perspective from India","author":"Kunal","year":"2021","journal-title":"Post. Med J."},{"key":"10.1016\/j.biopha.2022.112650_bib14","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.112650_bib15","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis","author":"Wells","year":"2012"},{"key":"10.1016\/j.biopha.2022.112650_bib16","article-title":"Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial","author":"Bonelli","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2022.112650_bib17","article-title":"Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose","author":"Gram","year":"2021","journal-title":"medRxiv"},{"issue":"10289","key":"10.1016\/j.biopha.2022.112650_bib18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2022.112650_bib19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous prime\u2013boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2022.112650_bib20","first-page":"1","article-title":"Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination","author":"Hammerschmidt","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.biopha.2022.112650_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jcm10173817","article-title":"An immunogenicity report for the comparison between heterologous and homologous prime\u2010boost schedules with chadox1\u2013s and bnt162b2 vaccines.","volume":"10","author":"Vall\u00e9e","year":"2021","journal-title":"J. Clin. Med."},{"issue":"10295","key":"10.1016\/j.biopha.2022.112650_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112650_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","author":"Hillus","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2022.112650_bib24","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity","author":"Gro\u00df","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2022.112650_bib25","article-title":"Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime","author":"Kant","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2022.112650_bib26","article-title":"Heterologous prime-boost immunization with CoronaVac and Convidecia","author":"Li","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2022.112650_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","author":"Schmidt","year":"2021","journal-title":"Am. J. Transpl."},{"issue":"10303","key":"10.1016\/j.biopha.2022.112650_bib28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biopha.2022.112650_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.112650_bib30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat. Med."},{"issue":"10305","key":"10.1016\/j.biopha.2022.112650_bib31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(21)01891-2","article-title":"SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S\/BNT162b2 vaccination","volume":"398","author":"Behrens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112650_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/vaccines9080857","article-title":"Heterologous ChAdOx1 nCoV-19\/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers","volume":"9","author":"Benning","year":"2021","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.biopha.2022.112650_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112650_bib34","article-title":"Heterologous ChAdOx1-S\/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2","author":"Dimeglio","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.112650_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/vaccines9080918","article-title":"mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects","volume":"9","author":"Fabricius","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2022.112650_bib36","article-title":"Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)","author":"Yorsaeng","year":"2021","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.biopha.2022.112650_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/22221751.2021.1937328","article-title":"Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine","volume":"10","author":"Liao","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.biopha.2022.112650_bib39","first-page":"396","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.biopha.2022.112650_bib40","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112650_bib41","doi-asserted-by":"crossref","unstructured":"Chiu, N.C., et al., To mix or not to mix? A rapid systematic review of heterologous prime\u2013boost covid-19 vaccination. Expert Review of Vaccines, 2021.","DOI":"10.1080\/14760584.2021.1971522"},{"issue":"25","key":"10.1016\/j.biopha.2022.112650_bib42","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2022.112650_bib43","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1097\/TP.0000000000003780","article-title":"Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.biopha.2022.112650_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jogn.2020.08.001","article-title":"Sex-based vaccine response in the context of COVID-19","volume":"49","author":"McCartney","year":"2020","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib45","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice","volume":"12","author":"Spencer","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2022.112650_bib46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2022.112650_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.112650_bib48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2022.112650_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize prime\/boost vaccine strategies: trained immunity as a new player in the game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib50","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1080\/22221751.2021.1957401","article-title":"Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.biopha.2022.112650_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg. Microbes Infect."},{"issue":"10295","key":"10.1016\/j.biopha.2022.112650_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0140-6736(21)01442-2","article-title":"Heterologous vaccine regimens against COVID-19","volume":"398","author":"Duarte-Salles","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112650_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/vaccines9101163","article-title":"The effects of heterologous immunization with prime-boost COVID-19 vaccination against SARS-CoV-2","volume":"9","author":"Ho","year":"2021","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.biopha.2022.112650_bib54","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3855\/jidc.15368","article-title":"Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response","volume":"15","author":"Ostadgavahi","year":"2021","journal-title":"J. Infect. Dev. Ctries"},{"key":"10.1016\/j.biopha.2022.112650_bib55","doi-asserted-by":"crossref","unstructured":"Lyski, Z.L., et al., Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two CLL patients. medRxiv, 2021.","DOI":"10.1101\/2021.09.02.21262146"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:44:04Z","timestamp":1760100244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"alternative-id":["S0753332222000385"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112650","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112650"}}